
Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – Investment analysts at HC Wainwright issued their FY2026 earnings estimates for shares of Basilea Pharmaceutica in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of $8.49 per share for the year. The consensus estimate for Basilea Pharmaceutica’s current full-year earnings is $8.49 per share.
Separately, Zacks Research initiated coverage on shares of Basilea Pharmaceutica in a research note on Monday. They set a “hold” rating on the stock. One equities research analyst has rated the stock with a Hold rating. Based on data from MarketBeat, Basilea Pharmaceutica has a consensus rating of “Hold”.
Basilea Pharmaceutica Price Performance
Basilea Pharmaceutica stock opened at $84.00 on Tuesday. Basilea Pharmaceutica has a 12-month low of $59.29 and a 12-month high of $84.00. The company has a 50-day moving average price of $77.55 and a 200 day moving average price of $70.18. The company has a debt-to-equity ratio of 0.44, a quick ratio of 5.97 and a current ratio of 6.60.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
